Article Text

Download PDFPDF
Letrozole in the management of advanced ovarian cancer: an old drug as a new targeted therapy
  1. Claudia Marchetti1,
  2. Francesca De Felice2,
  3. Raffaella Ergasti1,
  4. Giovanni Scambia1,3 and
  5. Anna Fagotti1,3
  1. 1 Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
  2. 2 Department of Radiological, Oncological and Anatomo Pathological Sciences, Azienda Policlinico Umberto I; Sapienza University of Rome, Rome, Italy
  3. 3 Catholic University Sacred Heart, Rome, Italy
  1. Correspondence to Professor Giovanni Scambia, Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma 00168, Italy; giovanni.scambia{at}


At present, there is no standard of care on the use of letrozole in ovarian cancer management. We performed a systematic review of the available literature addressing this issue. Data demonstrated a role for letrozole in ovarian cancer, in both the primary and recurrent setting. Letrozole, which has a favorable toxicity profile, seems to assure a prolonged recurrence-free interval, particularly when used as maintenance treatment, in low grade serous ovarian cancer; in recurrent cases it had also led to prolonged disease control. However, the optimal setting and biologically relevant patient population needs to be defined in larger trials.

  • ovarian cancer
  • medical oncology

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @annafagottimd

  • Contributors CM, AF made substantial contributions to the conception of the work. CM, FDF and RE made substantial contributions to the acquisition, analysis, interpretation of data, and drafting of the work. AF, GS revised it critically for important intellectual content. All authors gave final approval of the version published.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.